

REMARKS

Claims 1-4, 7-8, 11 and 24-28 are amended herein without prejudice or disclaimer of Applicant's right to pursue any canceled subject matter in a continuing application. Specifically, the claims have been amended in accordance with the Examiner's suggestion in the Advisory Action mailed 28 July 2010 to clarify that the chemical term "dUTP" recited in the pending claims solely designates unconjugated deoxyuridine triphosphate, consistent with the understanding of the skilled artisan that any modification to the compound would necessarily change the resulting chemical nomenclature as well. In particular, any modification of the uracil base requires further recitation of the moiety conjugated thereto and preferably the position of such modification, as demonstrated by the prior art recitations of Bio-11-dUTP in Bohlander et al. and Aminoallyl-dUTP in Mukai et al. Applicants note that unmodified and unconjugated deoxyuridine triphosphate is the only dUTP compound described and exemplified throughout the instant patent specification, and accordingly the instant amendment is in full compliance with 35 U.S.C. § 112 and in accordance with MPEP § 2163.

CONCLUSION

Applicants respectfully submit that the instant application is in condition for allowance. Entry of the amendments and an action passing this case to issue is therefore respectfully requested. Should there be any remaining issues that remain unresolved, the Examiner is encouraged to telephone the undersigned at (415) 356-3064.

Dated: 9/7/10
Customer Number: 28381
Arnold & Porter LLP
One Embarcadero Center, Suite 2200
San Francisco, California 94111
Telephone: (415) 356-3000
Facsimile: (415) 356-3099

Respectfully submitted,
ARNOLD & PORTER LLP

By: 

Todd A. Lorenz, Reg. No. 39,754

Filed Under 37 C.F.R. § 1.34